secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2025-05-09T23:59:59+00:00
Accession:  0001104659-25-046845
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma establishes $60M ATM with Leerink Partners; terminates prior HC Wainwright program
--------------------------------------------------------------------------------

- New ATM agreement with Leerink Partners to sell up to $60M of common stock; 3.0% commission on gross proceeds.
- Prior ATM with H.C. Wainwright for up to $40M terminated; ~$18.6M had been sold under that program.
- No costs or payments associated with termination of prior ATM.
- Sales will be made as at-the-market offerings on Nasdaq subject to customary conditions.
- Proceeds from any sales will be used for general corporate purposes as described in the prospectus supplement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465925046845/0001104659-25-046845-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465925046845/tm2514418d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-046845

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer